ASCO 2021 Lung Recap: Poseidon Trial: Durvalumab +/- Tremelimumab vs. Chemo Alone

POSEIDON: 4 year follow up of durvalumab and tremelimumab in NSCLCПодробнее

ASCO 2021 Lung Recap: Surgical Outcomes & Checkmate 816: Nivolumab in Early Stage NSCLCПодробнее

ASCO 2021 Lung Recap: Lurbinectedin in Small Cell Lung Cancer and the Failed Atlantis TrialПодробнее

DANUBE trial: Durvalumab alone or with tremelimumab for metastatic bladder cancerПодробнее

DUTRENEO: durvalumab and tremelimumab vs chemoПодробнее

ASCO 2021 Lung Recap: FDA Analysis of Immunotherapy With or Without Chemo in Adv NSCLC and Low PDL-1Подробнее

ASCO 2021 Lung Recap: IMpower010: Atezolizumab after Chemo in Non-Small Cell Lung CancerПодробнее

POSEIDON: durvalumab +/- tremelimumab + chemo in 1L mNSCLCПодробнее

ASCO 2021 Lung Recap: Circulatory Tumor DNAПодробнее

ASCO 2021 Lung Recap: MYLUNG Consortium: Overall Biomarker TestingПодробнее

Four chemo cycles given with durvalumab ± tremelimumab optimise response in patients with mNSCLCПодробнее

A Study of Chemotherapy With Durvalumab and Tremelimumab in NSCLCПодробнее

Durvalumab plus tremelimumab or durvalumab monotherapy in metastatic urothelial carcinomaПодробнее

Phase II Trial of Platinum-Etoposide Chemotherapy & Durvalumab with SBRT for Small Cell Lung CancerПодробнее

Updated results from the CASPIAN trial of durvalumab plus chemo in SCLCПодробнее

ASCO 2021 Lung Recap: CodeBreak 100: Sotorasib in KRAS G12C MutationПодробнее

Tremelimumab and durvalumab therapy in lung cancerПодробнее

HIMALAYA: Study of tremelimumab and durvalumab as first-line therapy in patients with uHCCПодробнее